Search Page

1

Combining radiotherapy with immunotherapy: the past, the present and the future.

Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P. Van Limbergen EJ, et al. Br J Radiol. 2017 Aug;90(1076):20170157. doi: 10.1259/bjr.20170157. Epub 2017 May 25. Br J Radiol. 2017. PMID: 28541096 Free PMC article. Review.

The advent of immunotherapy is currently revolutionizing the field of oncology, where different drugs are used to stimulate different steps in a failing cancer immune response chain. This review gives a basic overview of the immune response against cancer, as well as the h …

The advent of immunotherapy is currently revolutionizing the field of oncology, where different drugs are used to stimulate different …

Cite

Share

2

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses.

Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, Germeraad WTV, Van Limbergen EJ, Neri D, Dubois LJ, Lambin P. Rekers NH, et al. Oncoimmunology. 2018 Jan 16;7(4):e1414119. doi: 10.1080/2162402X.2017.1414119. eCollection 2018. Oncoimmunology. 2018. PMID: 29632732 Free PMC article.

Cite

Share

3

How Advances in Imaging Will Affect Precision Radiation Oncology.

Jaffray DA, Das S, Jacobs PM, Jeraj R, Lambin P. Jaffray DA, et al. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):292-298. doi: 10.1016/j.ijrobp.2018.01.047. Epub 2018 Jan 31. Int J Radiat Oncol Biol Phys. 2018. PMID: 29726358

Thus, more precise intervention will enable fractionation schedules that better interoperate with advances such as immunotherapy. ...

Thus, more precise intervention will enable fractionation schedules that better interoperate with advances such as immunotherapy. ...

Cite

Share

4

Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions.

Hartgerink D, van der Heijden B, De Ruysscher D, Postma A, Ackermans L, Hoeben A, Anten M, Lambin P, Terhaag K, Jochems A, Dekker A, Schoenmaekers J, Hendriks L, Zindler J. Hartgerink D, et al. Front Oncol. 2018 May 9;8:154. doi: 10.3389/fonc.2018.00154. eCollection 2018. Front Oncol. 2018. PMID: 29868476 Free PMC article. Review.

Several promising strategies are currently being investigated to further improve the indication and outcome of SRS for patients with BM: the effectivity and safety of SRS in patients with more than four BM, combining SRS with systemic therapy such as targeted agents or immunot …

Several promising strategies are currently being investigated to further improve the indication and outcome of SRS for patients with BM: the …

Cite

Share

5

Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.

Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Rekers NH, et al. Cancer Radiother. 2014 Oct;18(5-6):391-5. doi: 10.1016/j.canrad.2014.06.012. Epub 2014 Aug 30. Cancer Radiother. 2014. PMID: 25179250 Review.

This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy....

This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy....

Cite

Share

6

Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress.

Mowday AM, Guise CP, Ackerley DF, Minton NP, Lambin P, Dubois LJ, Theys J, Smaill JB, Patterson AV. Mowday AM, et al. Cancers (Basel). 2016 Jun 28;8(7):63. doi: 10.3390/cancers8070063. Cancers (Basel). 2016. PMID: 27367731 Free PMC article. Review.

The ability to target the immunosuppressive hypoxic tumour microenvironment using CDEPT may offer potential for synergy with recently developed immunotherapy strategies. ...

The ability to target the immunosuppressive hypoxic tumour microenvironment using CDEPT may offer potential for synergy with recently develo …

Cite

Share

7

Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects.

Zegers CM, Rekers NH, Quaden DH, Lieuwes NG, Yaromina A, Germeraad WT, Wieten L, Biessen EA, Boon L, Neri D, Troost EG, Dubois LJ, Lambin P. Zegers CM, et al. Clin Cancer Res. 2015 Mar 1;21(5):1151-60. doi: 10.1158/1078-0432.CCR-14-2676. Epub 2014 Dec 31. Clin Cancer Res. 2015. PMID: 25552483 Free article.

PURPOSE: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect of immunotherapy. ...

PURPOSE: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect of immun …

Cite

Share

8

Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.

Rekers NH, Zegers CM, Yaromina A, Lieuwes NG, Biemans R, Senden-Gijsbers BL, Losen M, Van Limbergen EJ, Germeraad WT, Neri D, Dubois L, Lambin P. Rekers NH, et al. Radiother Oncol. 2015 Sep;116(3):438-42. doi: 10.1016/j.radonc.2015.06.019. Epub 2015 Jun 29. Radiother Oncol. 2015. PMID: 26138057 Free article.

RESULTS: Tumour growth delay of L19-IL2 can be further improved by a single dose of RT administered before immunotherapy, but not during immunotherapy. ...

RESULTS: Tumour growth delay of L19-IL2 can be further improved by a single dose of RT administered before immunotherapy, but not dur …

Cite

Share

9

Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy.

Lambin P, Lieverse RIY, Eckert F, Marcus D, Oberije C, van der Wiel AMA, Guha C, Dubois LJ, Deasy JO. Lambin P, et al. Semin Radiat Oncol. 2020 Apr;30(2):187-193. doi: 10.1016/j.semradonc.2019.12.003. Semin Radiat Oncol. 2020. PMID: 32381298

There is now strong clinical and preclinical evidence that lymphocytes, for example, CD8(+) T cells, are key effectors of immunotherapy and that irradiation of large blood vessels, the heart, and lymphoid organs (including nodes, spleen, bones containing bone marrow, and t …

There is now strong clinical and preclinical evidence that lymphocytes, for example, CD8(+) T cells, are key effectors of immunotherapy …

Cite

Share

10

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2.

Rekers NH, Zegers CM, Germeraad WT, Dubois L, Lambin P. Rekers NH, et al. Oncoimmunology. 2015 Apr 2;4(8):e1021541. doi: 10.1080/2162402X.2015.1021541. eCollection 2015 Aug. Oncoimmunology. 2015. PMID: 26405576 Free PMC article.

Cite

Share